Skip to content

Pharmacokinetic Evaluation of Bioactive Components in a Test Substance Administered to Healthy Adults

Pharmacokinetic Evaluation of Bioactive Components in a Test Substance Administered to Healthy Adults - Pharmacokinetic Evaluation of Bioactive Components in a Test Substance Administered to Healthy Adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059605
Enrollment
20
Registered
2025-11-01
Start date
2025-11-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

Administration of test food

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Individuals who provided written informed consent to participate in the study. 2) Healthy Japanese adults aged between 20 and 69 years at the time of consent. 3) Postmenopausal women. 4) Individuals who were able to visit the study site and undergo the required examinations on the designated test days.

Exclusion criteria

Exclusion criteria: 1) Individuals deemed unsuitable for participation in the study by the investigator based on clinical laboratory tests or physical examinations. 2) Individuals with a history of serious disorders affecting major organs or systems, or those currently undergoing treatment, who are considered unsuitable for the study by the investigator. 3) Individuals with a current or past history of drug or food allergies. 4) Individuals who regularly take medications, including traditional Japanese (Kampo) medicines. 5) Individuals scheduled to receive any vaccination during the study period. 6) Individuals who donated 200 mL or more of whole blood within 4 weeks prior to the start of test food intake, or 400 mL or more within 12 weeks prior to the start of test food intake. 7) Individuals who tested positive for any of the following: HBs antigen, HCV antibody, HIV antigen/antibody, or syphilis serology. 8) Any other individuals deemed inappropriate for participation by the investigator or the study director.

Design outcomes

Primary

MeasureTime frame
Blood PK parameters

Countries

Japan

Contacts

Public ContactYoshifumi Kotani

Otsuka Pharmaceutical Co., Ltd. Nutraceuticals Research Institute

kotani.yoshifumi@otsuka.jp077-519-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026